@article{APS10483,
author = {Qiu-kai Lu and Chen Fan and Cai-gui Xiang and Bing Wu and Hui-min Lu and Chun-lan Feng and Xiao-qian Yang and Heng Li and Wei Tang},
title = {Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells},
journal = {Acta Pharmacologica Sinica},
volume = {43},
number = {2},
year = {2022},
keywords = {},
abstract = {Systemic sclerosis (SSc) is a life-threatening chronic connective tissue disease with the characteristics of skin fibrosis, vascular injury, and inflammatory infiltrations. Though inhibition of phosphodiesterase 4 (PDE4) has been turned out to be an effective strategy in suppressing inflammation through promoting the accumulation of intracellular cyclic adenosine monophosphate (cAMP), little is known about the functional modes of inhibiting PDE4 by apremilast on the process of SSc. The present research aimed to investigate the therapeutic effects and underlying mechanism of apremilast on SSc. Herein, we found that apremilast could markedly ameliorate the pathological manifestations of SSc, including skin dermal thickness, deposition of collagens, and increased expression of α-SMA. Further study demonstrated that apremilast suppressed the recruitment and activation of macrophages and T cells, along with the secretion of inflammatory cytokines, which accounted for the effects of apremilast on modulating the pro- fibrotic processes. Interestingly, apremilast could dose-dependently inhibit the activation of M1 and T cells in vitro through promoting the phosphorylation of CREB. In summary, our research suggested that inhibiting PDE4 by apremilast might provide a novel therapeutic option for clinical treatment of SSc patients.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/10483}
}